Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer

[1]  S. Sleijfer,et al.  Corrigendum to “Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies” [Cancer Treat. Rev. 40 (2014) 513–522] , 2014 .

[2]  S. Sleijfer,et al.  Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. , 2014, Cancer treatment reviews.

[3]  R. Muschel,et al.  The stromal compartments in pancreatic cancer: are there any therapeutic targets? , 2014, Cancer letters.

[4]  Kang Xu,et al.  PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. , 2013, Hepato-gastroenterology.

[5]  D. Powell,et al.  Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses. , 2013, Cancer research.

[6]  D. Dangaj,et al.  Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses , 2013, Oncoimmunology.

[7]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[8]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[9]  L. Wood.  Pancreatic Cancer Genomes: Toward Molecular Subtyping and Novel Approaches to Diagnosis and Therapy , 2013, Molecular Diagnosis & Therapy.

[10]  J. Taube,et al.  B7-H5 costimulates human T cells via CD28H , 2013, Nature Communications.

[11]  Li-xi Yang,et al.  Current status in chemotherapy for advanced pancreatic adenocarcinoma. , 2013, Anticancer research.

[12]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[13]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[14]  Gerald C. Chu,et al.  PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. , 2011, Cancer discovery.

[15]  Lieping Chen,et al.  Cell surface signaling molecules in the control of immune responses: a tide model. , 2011, Immunity.

[16]  Lieping Chen,et al.  Fine tuning the immune response through B7‐H3 and B7‐H4 , 2009, Immunological reviews.

[17]  Lieping Chen,et al.  Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.

[18]  H. Friess,et al.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma , 2004, The British journal of surgery.

[19]  G. Zhu,et al.  B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. , 2003, Immunity.

[20]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[21]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[22]  野見 武男.  Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer , 2007 .

[23]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[24]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.